We found that ECAR was highest in the three BE cell lines derived from patients with the highest genomic instability (CP-B, CP-C and CP-D) and lowest in the cell line derived from a patient with relatively more stable genome (CP-A), suggesting that a glycolytic phenotype was selected during the process of neoplastic progression. The gene discussed is CPB1; the disease is Barrett esophagus.